Erectile%20dysfunction Treatment

Treatment

Surgical Intervention

Penile Vascular Surgery

Arterial reconstructive surgery should be considered only in healthy men with recently acquired erectile dysfunction due to a focal arterial occlusion in the absence of a generalized vascular disease

Penile Drug Delivery (Implanted) Devices

May be tried before standard implants are used if erection is possible with pharmacological injection

Penile Implants

Considered final treatment for erectile dysfunction patients and should be reserved for patients who have failed other treatments
Irreversible and highly invasive
When performed by experienced surgeon has been associated with high rate of patient satisfaction
May have surgical complications and mechanical failure
Available classes of penile implants are inflatable (2- and 3- piece) and malleable devices
Surgical approaches include penoscrotal and infrapubic

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.